Recruiting
Phase 3

Remibrutinib

Sponsor:

Novartis Pharmaceuticals

Code:

NCT07700056

Conditions

Chronic Pruritus of Unknown Origin

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Placebo

Study Details

Brief summary:

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Conditions

Chronic Pruritus of Unknown Origin

Study ID

NCT07700056

Start date

Aug 24, 2026

Status verified date

Aug, 2026

Completion date

Apr 15, 2030

Anticipated

Primary completion date

Dec 19, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Participant must be ≥ 18 years of age, at the time of signing the informed consent.
  • Participants with chronic pruritus for at least 4 months prior to screening.
  • Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
  • Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
  • Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
  • Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
  • Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
  • The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
  • Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.

Key Exclusion Criteria:

  • Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
  • Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
  • Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected HIV infection.
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
  • History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.

Study Design

Enrollment

180 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Remibrutinib

Remibrutinib film coated tablets

experimental: Placebo followed by remibrutinib

Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

Interventions

Remibrutinib

Oral administration of remibrutinib

Placebo

Oral administration of matching placebo.

Primary outcome measure

  • Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS) [ Time Frame: Baseline, Week 12 ]

Central Contacts and Locations

Central contacts

Novartis Pharmaceuticals

1-888-669-6682novartis.email@novartis.com

Novartis Pharmaceuticals

+41613241111

Locations

Aeroallergy Research Laboratories

Recruiting

Savannah, Georgia, United States, 31406

Contacts

Susie Gault

+1 912 356 3619sgault@coastalallergy.net

Principal Investigator:

Brad Goodman

Dawes Fretzin Clinical Rea Group

Recruiting

Indianapolis, Indiana, United States, 46256

Contacts

Joannie Prusa

+1 317 516 5030#102jprusa@ecommunity.com

Principal Investigator:

Kenneth Dawes

Optima Research-Boardman

Recruiting

Boardman, Ohio, United States, 44512

Contacts

Sarah Merlo

smerlo@optimatrials.com

Principal Investigator:

Patrick Shannon

Austin Inst for Clinical Research

Recruiting

Pflugerville, Texas, United States, 78660

Contacts

Alivia Hernandez

+1 512 259 2545ahernandez@atxresearch.com

Principal Investigator:

Edward Lain

More Information

Sponsor

Novartis Pharmaceuticals

Last update posted

Sep 9, 2026

Last verified

Aug, 2026

Keywords

  • BTK inhibitor
  • chronic pruritus
  • chronic pruritus of unknown origin
  • CPUO
  • remibrutinib

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-09-09.